Welcome to our dedicated page for CLOVER HEALTH INVESTMENTS /DE SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOVER HEALTH INVESTMENTS /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOVER HEALTH INVESTMENTS /DE's regulatory disclosures and financial reporting.
Clover Health Investments, Corp. director Thomas L. Tran reported an equity award of Class A Common Stock. On January 6, 2026, he was granted 79,365 shares of Class A Common Stock, received as time-based restricted stock units (RSUs) at a price of $0 per share, meaning this was a compensatory grant rather than an open-market purchase.
According to the filing, these RSUs represent shares that will vest in full on the first anniversary of January 6, 2026, as long as Tran continues to serve as a director through that vesting date. After this award, Tran beneficially owns 180,029 shares of Class A Common Stock directly. This filing reflects routine director compensation in the form of equity.
Clover Health Investments, Corp. executive Jamie L. Reynoso, CEO for Medicare Advantage, reported a small insider sale of Class A common stock. On January 7, 2026, Reynoso sold 2,102 shares at a weighted average price of $2.53 per share in an open-market transaction. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025, which automates trades according to preset instructions. After this transaction, Reynoso directly beneficially owned 2,757,029 shares of Clover Health Class A common stock.
An insider of CLOV has filed a Form 144 indicating an intent to sell 2,102 shares of common stock through broker Morgan Stanley Smith Barney LLC on or about January 7, 2026 on the NASDAQ. These shares were acquired on January 3, 2026 as restricted stock units from the issuer. The filing notes that 424,304,898 common shares were outstanding. Over the prior three months, the same seller completed additional common stock sales labeled as “10b5-1 Sales”.
Clover Health Investments, Corp. insider Jamie L. Reynoso, who serves as CEO, Medicare Advantage, reported a small open-market sale of company stock. On 12/18/2025, Reynoso sold 4,913 shares of Class A common stock at a weighted average price of $2.61 per share, with individual trade prices ranging from $2.58 to $2.64. The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on March 13, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this sale, Reynoso beneficially owns 2,767,240 shares of Class A common stock, held in direct form.
Clover Health Investments, Corp.'s CEO for Medicare Advantage reported automatic share withholding transactions related to restricted stock unit vesting.
On December 14, 2025 and December 15, 2025, 12,567 and 8,691 shares of Class A Common Stock, respectively, were withheld at $2.7 per share to cover tax obligations when 6.25% quarterly tranches of time-based RSU grants from March 14, 2022 and September 16, 2022 vested. After these transactions, the officer directly beneficially owns 2,772,153 shares of Class A Common Stock, and the remaining RSUs continue to vest quarterly in 6.25% installments through March 14, 2026 and September 15, 2026, subject to continued service.
Clover Health Investments, Corp. reported an insider share withholding related to restricted stock vesting. On December 14, 2025, an officer serving as CEO, Counterpart Health had 98,411 shares of Class A common stock automatically withheld at $2.7 per share to cover tax obligations when a portion of previously granted restricted stock units vested.
After this transaction, the reporting person beneficially owned 1,051,674 Class A shares directly and 1,610,482 shares indirectly through a trust. The withheld shares correspond to 6.25% of the original time-based RSU grant made on March 14, 2022, which continues to vest in equal 6.25% quarterly installments through March 14, 2026, subject to continued service.
Clover Health Investments, Corp. reported an insider equity transaction by an officer serving as General Counsel & Secretary. On December 15, 2025, 6,404 shares of Class A common stock were withheld to cover tax obligations triggered by the vesting of time-based restricted stock units (RSUs).
The withheld shares correspond to 6.25% of the original RSU grant made on September 15, 2022. The remaining RSUs are scheduled to vest quarterly in equal 6.25% installments, with a final vesting date on September 15, 2026, subject to the reporting person’s continued service. Following this tax-withholding event, the reporting person beneficially owns 1,222,365 Class A shares directly.
Clover Health Investments Corp. insider tax withholding transaction
A Clover Health Investments Corp. officer, serving as General Counsel and Secretary, reported an automatic share withholding related to restricted stock units. On November 14, 2025, 7,459 shares of Class A common stock were withheld at a price of $2.47 per share to cover tax obligations triggered by the vesting of time-based restricted stock units granted on February 14, 2022. After this transaction, the reporting person beneficially owned 1,228,769 shares of Class A common stock. The underlying restricted stock units vest in quarterly installments of 6.25%, with the final vesting date scheduled for February 14, 2026, conditioned on continued service.
Clover Health (CLOV) reported an insider Form 4 for CEO and Director Andrew Toy. On 11/08/2025, 85,535 shares of Class A common stock were withheld at $2.67 per share under transaction code F, reflecting automatic share withholding to cover taxes upon RSU vesting.
The vesting represented 6.25% of RSUs granted on 08/08/2022. Following the transaction, Toy beneficially owns 9,837,447 shares directly. The remaining RSUs vest quarterly in equal 6.25% installments through 08/08/2026, subject to continued service.
Clover Health Investments (CLOV) furnished a Regulation FD update, publishing written responses to select shareholder questions tied to its third quarter 2025 earnings announcement. The Supplemental Shareholder Q&A is included as Exhibit 99.1 and is also available on the company’s investor relations website. The company states this information is furnished, not filed, and is not incorporated by reference unless specifically noted.